Výsledky vyhledávání - "Paul M Peloso"

Akademický článek

Once-Daily, Controlled-Release Tramadol and Sustained-Release Diclofenac Relieve Chronic Pain due to Osteoarthritis: A Randomized Controlled Trial

Autor: André D Beaulieu, Paul M Peloso, Boulos Haraoui, William Bensen, Glen Thomson, John Wade, Patricia Quigley, John Eisenhoffer, Zoltan Harsanyi, Andrew C Darke

Publikováno v: Pain Research and Management, Vol 13, Iss 2, Pp 103-110 (2008)

OBJECTIVE: The present study was a randomized, parallel, double-blind comparison between controlled-release (CR) tramadol and sustained-release (SR) diclofenac in patients with chronic pain due to osteoarthritis of the hips and/or knees.

Externí odkaz: https://doaj.org/article/de0f352f721d47bb89361bb06df21988

Zobrazit plný text záznamu

Akademický článek

Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis

Autor: Susanne Klint, Joachim Feldwisch, Lindvi Gudmundsdotter, Karin Dillner Bergstedt, Elin Gunneriusson, Ingmarie Höidén Guthenberg, Anders Wennborg, Andrew C. Nyborg, Amol P. Kamboj, Paul M. Peloso, David Bejker, Fredrik Y. Frejd

Publikováno v: mAbs, Vol 15, Iss 1 (2023)

ABSTRACTPsoriasis, an immune-mediated inflammatory disease, affects nearly 125 million people globally. The interleukin (IL)-17A homodimer is a key driver of psoriasis and other autoimmune diseases, including psoriatic arthritis, axial spondyloarthri

Externí odkaz: https://doaj.org/article/c8401aa19f3c478fa57e57df7df533f1

Zobrazit plný text záznamu

Akademický článek

A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study

Autor: John K. Botson, John R. P. Tesser, Ralph Bennett, Howard M. Kenney, Paul M. Peloso, Katie Obermeyer, Yang Song, Brian LaMoreaux, Lin Zhao, Yan Xin, Jason Chamberlain, Srini Ramanathan, Michael E. Weinblatt, Jeff Peterson

Publikováno v: Arthritis Research & Therapy, Vol 24, Iss 1, Pp 1-12 (2022)

Abstract Background Publications suggest immunomodulation co-therapy improves responder rates in uncontrolled/refractory gout patients undergoing pegloticase treatment. The MIRROR open-label trial showed a 6-month pegloticase + methotrexate co-therap

Externí odkaz: https://doaj.org/article/4fc2a178d072458a9a48f53d9921ee85

Zobrazit plný text záznamu

Dual-Energy Computed Tomography Has Additional Prognostic Value Over Clinical Measures in Gout Including Tophi: A Systematic Literature Review

Autor: Sally K. Stauder, Paul M. Peloso

Publikováno v: The Journal of rheumatology. 49(11)

Objective This systematic literature review determined whether there is clinical utility for dual-energy computed tomography (DECT) to inform on prognosis for patients with gout. With DECT, individualized treatment plans could be developed based on t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07cdeb240415d43295a12295155c1567
https://pubmed.ncbi.nlm.nih.gov/35840151

Zobrazit plný text záznamu

A Multicentre, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase (MIRROR): 12-Month Efficacy, Safety, Immunogenicity, and Pharmacokinetic Findings of an Open-label Study

Autor: Michael E. Weinblatt, Howard M. Kenney, Lin Zhao, Brian LaMoreaux, John K. Botson, Ralph Bennett, Yang Song, Yan Xin, Jeff Peterson, Katie Obermeyer, Srini Ramanathan, Paul M. Peloso, John Tesser, Jason Chamberlain

Background: Publications suggest immunomodulation co-therapy improves responder rates in uncontrolled/refractory gout patients undergoing pegloticase treatment. The MIRROR open-label trial showed a 6-month pegloticase+methotrexate co-therapy responde

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1e8d628a0ca4577fe49d6b4a9a7d19e6
https://doi.org/10.21203/rs.3.rs-951365/v1

Zobrazit plný text záznamu

Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR)

Autor: Howard M. Kenney, Katie Obermeyer, John K. Botson, Michael E. Weinblatt, John Tesser, Ralph Bennett, Jeff Peterson, Paul M. Peloso, Brian LaMoreaux

Publikováno v: The Journal of rheumatology. 48(5)

ObjectiveTo examine the efficacy and safety of pegloticase in combination with methotrexate (MTX) in patients with uncontrolled gout in an exploratory, open-label clinical trial (ClinicalTrials.gov: NCT03635957) prior to a randomized, controlled tria

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71b145fbfc52eea51b1986c6b2bfe5f6
https://pubmed.ncbi.nlm.nih.gov/32934137

Zobrazit plný text záznamu

Phase II Study of ABT‐122, a Tumor Necrosis Factor– and Interleukin‐17A–Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate

Autor: Michael E. Weinblatt, Ahmed A. Othman, Kun Chen, Yihan Li, Mark C. Genovese, J. Liu, Neil Wishart, Heikki T. Mansikka, Paul M. Peloso, Philip J. Mease, Amit Khatri

Publikováno v: Arthritis & Rheumatology (Hoboken, N.j.)

OBJECTIVE To investigate the safety and efficacy of ABT-122, a tumor necrosis factor (TNF)- and interleukin-17A (IL-17A)-targeted dual variable domain immunoglobulin, in patients with active psoriatic arthritis (PsA) who have experienced an inadequat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af37b00ea8e09937f1550fb6a8672ce8
http://europepmc.org/articles/PMC6221045

Zobrazit plný text záznamu

Pharmacokinetics, Safety, and Tolerability of the Dual Inhibitor of Tumor Necrosis Factor‐α and Interleukin 17A, ABBV‐257, in Healthy Volunteers and Patients With Rheumatoid Arthritis

Autor: Ralf Loebbert, Ahmed A. Othman, Paul M. Peloso, Amit Khatri

Publikováno v: Clinical Pharmacology in Drug Development. 8:492-502

The dual-variable domain immunoglobulin ABBV-257 binds tumor necrosis factor-α and interleukin 17A. Following single ascending doses ( 0.3, 1.0, and 3.0 mg/kg intravenously; 0.3 and 3.0 mg/kg subcutaneously) in a randomized, double-blind, placebo-co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd83139a0656c0d4ed123abbf36721ef
https://doi.org/10.1002/cpdd.611

Zobrazit plný text záznamu

Akademický článek

Definition of Nonresponse to Analgesic Treatment of Arthritic Pain: An Analytical Literature Review of the Smallest Detectable Difference, the Minimal Detectable Change, and the Minimal Clinically Important Difference on the Pain Visual Analog Scale

Autor: Melissa E. Stauffer, Stephanie D. Taylor, Douglas J. Watson, Paul M. Peloso, Alan Morrison

Publikováno v: International Journal of Inflammation, Vol 2011 (2011)

Our objective was to develop a working definition of nonresponse to analgesic treatment of arthritis, focusing on the measurement of pain on the 0–100 mm pain visual analog scale (VAS). We reviewed the literature to assess the smallest detectable d

Externí odkaz: https://doaj.org/article/1b85d4c0ee3142b48503a1442c74dcc9

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání